Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person18
Ocugen, Inc.
Company
OCULUS INC.
Company
Inogen Inc
Company
AMGEN INC
Company
EXAGEN INC.
Company
Axogen, Inc.
Company
BIOGEN INC.
Company
Tevogen Inc.
Company
TECOGEN INC.
Company
PRECIGEN, INC.
Company
Oura Inc.
Company
Okta, Inc.
Company
Oklo Inc.
Company
OOMA INC
Company
ORAGENICS INC
Company
OppFi Inc.
Company
Owlet, Inc.
Company
Ondas Inc.
Company
Primary record11
Ocugen, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended September 30, 2026. The Company
Ocugen, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. Attached as Exhibit 99.1 and incorporated herein by reference is a presentation that Ocugen, Inc. (the Company or Ocugen ) will post on its website on October 15, 2026 and may use from
Ocugen, Inc. filed 8-K
Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2026, Ocugen, Inc. (the Company or Ocugen ) entered into an Exclusive License Agreement (the License Agreement ) with Roots Pharmaceutical Company WLL
Ocugen, Inc. filed 4
SEC form 4 filed by Ocugen, Inc. (CIK 1372299) on 2026-10-13.
Ocugen, Inc. filed 8-K
Item 5.07 Submission of Matters to a Vote of Security Holders. On October 5, 2026, Ocugen, Inc. (the Company ) reconvened its Special Meeting of Stockholders (the Special Meeting ) virtually, which had been adjourned on
Ocugen, Inc. filed 8-K
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 21, 2026, Ocugen, Inc. (the Company ) held a Special Meeting of Stockholders (the Special Meeting ) virtually, which was adjourned to October 5,
Ocugen, Inc. filed 4
SEC form 4 filed by Ocugen, Inc. (CIK 1372299) on 2026-09-11.
SCYNEXIS INC filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer On September 9, 2026, the
Ocugen, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. Attached as Exhibit 99.1 and incorporated herein by reference is a presentation that Ocugen, Inc. (the “Company” or “Ocugen”) will post on its website on September 8, 2026 and may use
Janus Henderson Group Ltd. filed SCHEDULE 13G/A
0001274173-26-000196.txt : 20260813 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001274173-25-000339 0001274173 XXXXXXXX LIVE 1 Common Stock 06/30/2026 0001372299 OCUGEN, INC. 67577C105 11 GREAT VALLEY PARKWAY
Ocugen, Inc. filed SCHEDULE 13G
0000093751-26-000513.txt : 20260807 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0000093751 XXXXXXXX LIVE COMMON STOCK 06/30/2026 0001372299 OCUGEN INC 67577C105 11 GREAT VALLEY PARKWAY MALVERN PA 19355 Rule 13d-1(b